|
Scleroderma Registry Clinical Trials Facts presented on Clinical Trials Search is not designed to be a substitute for certified medical advice, travels to or treatment with a real dr.. We aren't doctors. Always consult your mD on Scleroderma Registry conditions. Clinical Trials Search.org is a website dedicated to listing clinical research studies in human subjects. Scleroderma Registry Clinical research trials and Scleroderma Registry medical trials occur in many of places across the U.S.A.. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally assess the effectiveness of new does drugs. The role of the studies / undertakings is to figure out certain human healthcare questions. Clinical trials are a popular means for doctors, government agencies, and private sector corporations to locate treatments for all forms of circumstances, including Scleroderma Registry. Scleroderma Registry Clinical Trials and other clinical trials permit volunteers to get medical treatment options before they are available to the masses. Most times the human subjects acquire treatment for free of charge, and sometimes they are paid for their time. Occasionally there is a cost for a Scleroderma Registry clinical trial. Participants oftentimes recieve the finest healthcare available for their Scleroderma Registry condition. Dangers are a reality, nonetheless, and might include extra or frequent physician calls, health hazards (potentially life-endangering), and/or the treatment being ineffectual. Trials are federally regulated with strict guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "S" Clinical Trials Conditions > Scleroderma Registry  Scleroderma Registry
Scleroderma Registry
For Condition: Systemic Sclerosis,Scleroderma
Status: Recruiting
Sponsor(s): National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) ,
Synopsis: Scleroderma is likely caused by a combination of factors, including an external trigger (infection or other exposure) and a genetic predisposition. The Scleroderma Registry will conduct genetic analyses for disease-related genes in patients with scleroderma and their family members (parents, brothers, and sisters).
Details: Scleroderma refers to a group of diseases that involve the abnormal growth of connective tissue, which supports the skin and internal organs. Scleroderma can affect the skin, making it hard and tight; it can also damage the blood vessels and internal organs such as the heart, lungs, and kidneys. Estimates for the number of people in the United States with the systemic (body-wide) form of scleroderma range from 40,000 to 165,000. The number of people with all scleroderma-related disorders is between 250,000 and 992,500. Researchers believe that several factors interact to produce scleroderma, including abnormal immune activity, potential environmental triggers, and genetic makeup. Scleroderma is not passed on from parents to child, but certain genes may make a person more likely to develop the disease. The goals of this project are to identify the genes that influence disease susceptibility and expression in systemic scleroderma and to establish a repository of DNA, plasma, and serum samples from single case scleroderma families, multicase families, and healthy unrelated volunteers for the use of researchers interested in studying this disease. Participants in the Registry will have a phone interview regarding disease characteristics and family history. Participants will be sent a blood kit to get a blood sample drawn locally for shipment to the Registry lab. Blood samples will be made available (anonymously) for studies by researchers around the country. In some cases, participants will be asked to sign a release of medical information so that medical records can be obtained to verify the diagnosis.
Eligibility:
Study Type: Observational, Natural History, Cross-Sectional, Case Control, Retrospective/Prospective Study
Minimum Age/Maximum Age: /
Genders: Both
Protocol Entry Criteria: Inclusion Criteria - Diagnosis of systemic sclerosis or family members of patients with systemic sclerosis Or - Healthy volunteer with no autoimmune disease and without a first-degree relative with a systemic autoimmune disease
Total Enrollment: 5000
Location and Contact Information:
Overall Study Official:
MaureenMayes, Principal Investigator, University of Texas
University of Texas - Houston Medical School *Recruiting*
Houston, Texas, 77030
United States
Recruiting Marilyn Perry 713-500-7162
Additional Information:
Study ID Numbers: NIAMS-108;
Study Start Date: September 2000
Record last reviewed: March 2004
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00074568
Other Systemic Sclerosis Studies:
1. Phase III Randomized, Double-Blind, Placebo-Controlled Study of Oral Iloprost for Raynaud's Phenomenon Secondary to Systemic Sclerosis
2. Genetic Study of the FBN1 Gene and Fibrillin-1 Abnormalities in Choctaw Native Americans and Other Patients with Systemic Sclerosis
3. Psychological Treatments for Scleroderma
4. Efficacy and Safety of Oral Bosentan on Healing/Prevention of Digital (Finger) Ulcers in Scleroderma Patients
5. Phase II Study of Recombinant Relaxin for Progressive Systemic Sclerosis
Related Studies:
Other Systemic Sclerosis Clinical Trials
Other Texas Clinical Trials
Other Houston Clinical Trials
Scleroderma Registry
|
|
|
|
|
|
|
|
